Payment overview · 2025
General Payments
$2,959.97
146 reported records · 35 companies
Healthcare provider profile · identity verified
Kyung H Chu
Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner|Adult Health · BELLEVILLE, NJ · NPI 1962724393
Verified facts
What the public records show
CMS Open Payments records show Kyung H Chu received $2,959.97 in general payments during 2025 across 146 reported records.
E.R. Squibb & Sons, L.L.C. accounted for 12.2% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 59 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Brukinsa, Nubeqa, Tagrisso, Venclexta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VENCLEXTA as an associated drug or biological on 10417 records involving 4944 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Venclexta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TAGRISSO as an associated drug or biological on 5285 records involving 2776 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Tagrisso by this doctor in 2024.
Bayer Healthcare Pharmaceuticals Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Nubeqa as an associated drug or biological on 24369 records involving 9557 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Nubeqa by this doctor in 2024.
BeOne Medicines USA, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRUKINSA as an associated drug or biological on 10251 records involving 4941 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Brukinsa by this doctor in 2024.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 136 claims for Eliquis by this doctor in 2024.
Genentech USA, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Venclexta as an associated drug or biological on 2896 records involving 2018 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Venclexta by this doctor in 2024.
Janssen Biotech, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported XARELTO as an associated drug or biological on 24 records involving 23 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Xarelto by this doctor in 2024.
Janssen Pharmaceuticals, Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported XARELTO as an associated drug or biological on 28 records involving 28 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Xarelto by this doctor in 2024.
Merck Sharp & Dohme LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LENVIMA as an associated drug or biological on 66 records involving 58 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Lenvima by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 136 claims for Eliquis by this doctor in 2024.
Takeda Pharmaceuticals U.S.A., Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NINLARO as an associated drug or biological on 3835 records involving 2551 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Ninlaro by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $362.10 | 12.2% | 16 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $342.26 | 11.6% | 17 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $233.82 | 7.9% | 8 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $218.76 | 7.4% | 13 | 2025 |
| Adaptive Biotechnologies Corporation | Unresolved — no canonical attribution shown | $177.45 | 6.0% | 8 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $174.24 | 5.9% | 6 | 2025 |
| Janssen Biotech, Inc. | Unresolved — no canonical attribution shown | $173.56 | 5.9% | 6 | 2025 |
| Daiichi Sankyo Inc. | Unresolved — no canonical attribution shown | $173.24 | 5.8% | 10 | 2025 |
| Incyte Corporation | Unresolved — no canonical attribution shown | $107.68 | 3.6% | 6 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $94.04 | 3.2% | 6 | 2025 |
| GENZYME CORPORATION | Unresolved — no canonical attribution shown | $88.28 | 3.0% | 4 | 2025 |
| BeOne Medicines USA, Inc. | Unresolved — no canonical attribution shown | $82.99 | 2.8% | 4 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $78.06 | 2.6% | 4 | 2025 |
| Genentech USA, Inc. | Unresolved — no canonical attribution shown | $71.51 | 2.4% | 4 | 2025 |
| Karyopharm Therapeutics Inc. | Unresolved — no canonical attribution shown | $68.06 | 2.3% | 4 | 2025 |
| Geron Corporation | Unresolved — no canonical attribution shown | $63.71 | 2.1% | 4 | 2025 |
| Takeda Pharmaceuticals U.S.A., Inc. | Unresolved — no canonical attribution shown | $55.76 | 1.9% | 3 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $39.96 | 1.4% | 2 | 2025 |
| Regeneron Healthcare Solutions, Inc. | Unresolved — no canonical attribution shown | $38.85 | 1.3% | 2 | 2025 |
| Alexion Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $35.75 | 1.2% | 2 | 2025 |
| Stemline Therapeutics Inc. | Unresolved — no canonical attribution shown | $33.90 | 1.1% | 2 | 2025 |
| EMD Serono, Inc. | Unresolved — no canonical attribution shown | $32.88 | 1.1% | 2 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $21.74 | 0.7% | 1 | 2025 |
| Verastem, Inc. | Unresolved — no canonical attribution shown | $20.30 | 0.7% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $19.49 | 0.7% | 1 | 2025 |
| PharmaEssentia USA Corporation | Unresolved — no canonical attribution shown | $18.39 | 0.6% | 1 | 2025 |
| Legend Biotech USA Inc. | Unresolved — no canonical attribution shown | $18.07 | 0.6% | 1 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $17.72 | 0.6% | 1 | 2025 |
| Agios Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $17.17 | 0.6% | 1 | 2025 |
| Aimmune Therapeutics, Inc. | Unresolved — no canonical attribution shown | $16.85 | 0.6% | 1 | 2025 |
| SOBI, INC | Unresolved — no canonical attribution shown | $16.71 | 0.6% | 1 | 2025 |
| Syndax Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $16.00 | 0.5% | 1 | 2025 |
| PUMA BIOTECHNOLOGY, INC. | Unresolved — no canonical attribution shown | $14.99 | 0.5% | 1 | 2025 |
| ARRAY BIOPHARMA INC | Unresolved — no canonical attribution shown | $14.62 | 0.5% | 1 | 2025 |
| Janssen Pharmaceuticals, Inc | Unresolved — no canonical attribution shown | $1.06 | 0.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $2,676.95 | 143 |
| Long term medical supply or device loan | $183.03 | 2 |
| Education | $99.99 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| OPDIVO Normalized: opdivo |
Biological | E.R. Squibb & Sons, L.L.C. | $362.10 | 16 | 2025 |
Source payment records
|
|||||
| KISQALI Normalized: kisqali |
Drug | Novartis Pharmaceuticals Corporation | $247.43 | 6 | 2025 |
Source payment records
|
|||||
| ENHERTU Normalized: enhertu |
Biological, Drug | AstraZeneca Pharmaceuticals LP, Daiichi Sankyo Inc. | $244.47 | 14 | 2025 |
Source payment records
|
|||||
| clonoSEQ Normalized: clonoseq |
Device | Adaptive Biotechnologies Corporation | $177.45 | 8 | 2025 |
Source payment records
|
|||||
| OJJAARA Normalized: ojjaara |
Drug | GlaxoSmithKline, LLC. | $151.15 | 3 | 2025 |
Source payment records
|
|||||
| VENCLEXTA Normalized: venclexta |
Drug | ABBVIE INC. | $142.57 | 4 | 2025 |
Source payment records
|
|||||
| DARZALEX Normalized: darzalex |
Biological | Janssen Biotech, Inc., Janssen Pharmaceuticals, Inc | $129.07 | 4 | 2025 |
Source payment records
|
|||||
| TALVEY Normalized: talvey |
Biological | Janssen Biotech, Inc. | $128.01 | 3 | 2025 |
Source payment records
|
|||||
| TECVAYLI Normalized: tecvayli |
Biological | Janssen Biotech, Inc., Janssen Pharmaceuticals, Inc | $117.96 | 3 | 2025 |
Source payment records
|
|||||
| JAKAFI Normalized: jakafi |
Drug | Incyte Corporation | $107.68 | 6 | 2025 |
Source payment records
|
|||||
| LYNPARZA Normalized: lynparza |
Biological, Drug | AstraZeneca Pharmaceuticals LP, Merck Sharp & Dohme LLC | $97.17 | 6 | 2025 |
Source payment records
|
|||||
| KEYTRUDA Normalized: keytruda |
Biological | Merck Sharp & Dohme LLC | $94.04 | 6 | 2025 |
Source payment records
|
|||||
| Nubeqa Normalized: nubeqa |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $78.06 | 4 | 2025 |
Source payment records
|
|||||
| XPOVIO Normalized: xpovio |
Drug | Karyopharm Therapeutics Inc. | $68.06 | 4 | 2025 |
Source payment records
|
|||||
| BRUKINSA Normalized: brukinsa |
Drug | BeOne Medicines USA, Inc. | $67.79 | 3 | 2025 |
Source payment records
|
|||||
| RYTELO Normalized: rytelo |
Drug | Geron Corporation | $63.71 | 4 | 2025 |
Source payment records
|
|||||
| JEMPERLI Normalized: jemperli |
Biological | GlaxoSmithKline, LLC. | $61.90 | 4 | 2025 |
Source payment records
|
|||||
| ZEJULA Normalized: zejula |
Drug | GlaxoSmithKline, LLC. | $61.90 | 4 | 2025 |
Source payment records
|
|||||
| Xofigo Normalized: xofigo |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $56.12 | 3 | 2025 |
Source payment records
|
|||||
| WAYRILZ Normalized: wayrilz |
Drug | GENZYME CORPORATION | $45.36 | 2 | 2025 |
Source payment records
|
|||||
| Itovebi Normalized: itovebi |
Biological | Genentech USA, Inc. | $41.51 | 2 | 2025 |
Source payment records
|
|||||
| JAYPIRCA Normalized: jaypirca |
Drug | Lilly USA, LLC | $39.96 | 2 | 2025 |
Source payment records
|
|||||
| VERZENIO Normalized: verzenio |
Drug | Lilly USA, LLC | $39.96 | 2 | 2025 |
Source payment records
|
|||||
| SCEMBLIX Normalized: scemblix |
Drug | Novartis Pharmaceuticals Corporation | $39.42 | 4 | 2025 |
Source payment records
|
|||||
| FRUZAQLA Normalized: fruzaqla |
Drug | Takeda Pharmaceuticals U.S.A., Inc. | $39.02 | 2 | 2025 |
Source payment records
|
|||||
| LIBTAYO Normalized: libtayo |
Biological | Regeneron Healthcare Solutions, Inc. | $38.85 | 2 | 2025 |
Source payment records
|
|||||
| ORGOVYX Normalized: orgovyx |
Drug | PFIZER INC., Sumitomo Pharma America, Inc. | $37.21 | 2 | 2025 |
Source payment records
|
|||||
| ULTOMIRIS Normalized: ultomiris |
Biological | Alexion Pharmaceuticals, Inc. | $35.75 | 2 | 2025 |
Source payment records
|
|||||
| LUTATHERA Normalized: lutathera |
Drug | Novartis Pharmaceuticals Corporation | $35.05 | 3 | 2025 |
Source payment records
|
|||||
| TAGRISSO Normalized: tagrisso |
Drug | AstraZeneca Pharmaceuticals LP | $34.44 | 2 | 2025 |
Source payment records
|
|||||
| KEYTRUDA QLEX Normalized: keytruda qlex |
Biological | Merck Sharp & Dohme LLC | $30.38 | 2 | 2025 |
Source payment records
|
|||||
| Stivarga Normalized: stivarga |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $21.94 | 1 | 2025 |
Source payment records
|
|||||
| Vitrakvi Normalized: vitrakvi |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $21.94 | 1 | 2025 |
Source payment records
|
|||||
| Vyloy Normalized: vyloy |
Drug | Astellas Pharma US Inc | $21.74 | 1 | 2025 |
Source payment records
|
|||||
| SARCLISA Normalized: sarclisa |
Biological | GENZYME CORPORATION | $21.16 | 1 | 2025 |
Source payment records
|
|||||
| BLENREP Normalized: blenrep |
Biological | GlaxoSmithKline, LLC. | $20.77 | 1 | 2025 |
Source payment records
|
|||||
| Fabhalta Normalized: fabhalta |
Drug | Novartis Pharmaceuticals Corporation | $20.36 | 4 | 2025 |
Source payment records
|
|||||
| AVMAPKI FAKZYNJA CO-PACK Normalized: avmapki fakzynja co pack |
Drug | Verastem, Inc. | $20.30 | 1 | 2025 |
Source payment records
|
|||||
| TALZENNA Normalized: talzenna |
Drug | PFIZER INC. | $19.49 | 1 | 2025 |
Source payment records
|
|||||
| XTANDI Normalized: xtandi |
Drug | PFIZER INC. | $19.49 | 1 | 2025 |
Source payment records
|
|||||
| ELZONRIS Normalized: elzonris |
Drug | Stemline Therapeutics Inc. | $19.00 | 1 | 2025 |
Source payment records
|
|||||
| BESREMI Normalized: besremi |
Drug | PharmaEssentia USA Corporation | $18.39 | 1 | 2025 |
Source payment records
|
|||||
| CARVYKTI Normalized: carvykti |
Biological | Legend Biotech USA Inc. | $18.07 | 1 | 2025 |
Source payment records
|
|||||
| PYRUKYND Normalized: pyrukynd |
Drug | Agios Pharmaceuticals, Inc. | $17.17 | 1 | 2025 |
Source payment records
|
|||||
| ZENPEP Normalized: zenpep |
Drug | Aimmune Therapeutics, Inc. | $16.85 | 1 | 2025 |
Source payment records
|
|||||
| ICLUSIG Normalized: iclusig |
Drug | Takeda Pharmaceuticals U.S.A., Inc. | $16.74 | 1 | 2025 |
Source payment records
|
|||||
| Vonjo Normalized: vonjo |
Drug | SOBI, INC | $16.71 | 1 | 2025 |
Source payment records
|
|||||
| ERLEADA Normalized: erleada |
Drug | Janssen Biotech, Inc. | $16.56 | 1 | 2025 |
Source payment records
|
|||||
| ELAHERE Normalized: elahere |
Drug | ABBVIE INC. | $16.50 | 1 | 2025 |
Source payment records
|
|||||
| EVUSHELD Normalized: evusheld |
Drug | AstraZeneca Pharmaceuticals LP | $16.49 | 1 | 2025 |
Source payment records
|
|||||
| NIKTIMVO Normalized: niktimvo |
Drug | Syndax Pharmaceuticals, Inc. | $16.00 | 1 | 2025 |
Source payment records
|
|||||
| TEVIMBRA Normalized: tevimbra |
Drug | BeOne Medicines USA, Inc. | $15.20 | 1 | 2025 |
Source payment records
|
|||||
| EMRELIS Normalized: emrelis |
Drug | ABBVIE INC. | $15.17 | 1 | 2025 |
Source payment records
|
|||||
| Polivy Normalized: polivy |
Biological | Genentech USA, Inc. | $15.00 | 1 | 2025 |
Source payment records
|
|||||
| Tecentriq Normalized: tecentriq |
Biological | Genentech USA, Inc. | $15.00 | 1 | 2025 |
Source payment records
|
|||||
| NERLYNX Normalized: nerlynx |
Drug | PUMA BIOTECHNOLOGY, INC. | $14.99 | 1 | 2025 |
Source payment records
|
|||||
| Orserdu Normalized: orserdu |
Drug | Stemline Therapeutics Inc. | $14.90 | 1 | 2025 |
Source payment records
|
|||||
| LORBRENA Normalized: lorbrena |
Drug | ARRAY BIOPHARMA INC | $14.62 | 1 | 2025 |
Source payment records
|
|||||
| RYBREVANT Normalized: rybrevant |
Drug | Janssen Biotech, Inc. | $12.08 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| BRUKINSA brukinsa |
2025 | Brukinsa | 2024 | 13 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Nubeqa nubeqa |
2025 | Nubeqa | 2024 | 18 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TAGRISSO tagrisso |
2025 | Tagrisso | 2024 | 12 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| VENCLEXTA venclexta |
2025 | Venclexta | 2024 | 18 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VENCLEXTA open payments reported associated product |
CMS Open Payments — General Payments 10417 supporting records · 4944 recipient NPIs · example record 1201353144 |
Venclexta · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | TAGRISSO open payments reported associated product |
CMS Open Payments — General Payments 5285 supporting records · 2776 recipient NPIs · example record 1206131546 |
Tagrisso · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| Bayer Healthcare Pharmaceuticals Inc. Exact reporting entity; no affiliate inference |
2025 | Nubeqa open payments reported associated product |
CMS Open Payments — General Payments 24369 supporting records · 9557 recipient NPIs · example record 1225434669 |
Nubeqa · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| BeOne Medicines USA, Inc. Exact reporting entity; no affiliate inference |
2025 | BRUKINSA open payments reported associated product |
CMS Open Payments — General Payments 10251 supporting records · 4941 recipient NPIs · example record 1202883638 |
Brukinsa · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
136 | 46 |
| Genentech USA, Inc. Exact reporting entity; no affiliate inference |
2025 | Venclexta open payments reported associated product |
CMS Open Payments — General Payments 2896 supporting records · 2018 recipient NPIs · example record 1211488584 |
Venclexta · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| Janssen Biotech, Inc. Exact reporting entity; no affiliate inference |
2025 | XARELTO open payments reported associated product |
CMS Open Payments — General Payments 24 supporting records · 23 recipient NPIs · example record 1174259978 |
Xarelto · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
| Janssen Pharmaceuticals, Inc Exact reporting entity; no affiliate inference |
2025 | XARELTO open payments reported associated product |
CMS Open Payments — General Payments 28 supporting records · 28 recipient NPIs · example record 1174296970 |
Xarelto · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
| Merck Sharp & Dohme LLC Exact reporting entity; no affiliate inference |
2025 | LENVIMA open payments reported associated product |
CMS Open Payments — General Payments 66 supporting records · 58 recipient NPIs · example record 1237995778 |
Lenvima · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
136 | 46 |
| Takeda Pharmaceuticals U.S.A., Inc. Exact reporting entity; no affiliate inference |
2025 | NINLARO open payments reported associated product |
CMS Open Payments — General Payments 3835 supporting records · 2551 recipient NPIs · example record 1223616278 |
Ninlaro · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Eliquis | Apixaban | 136 | 46 |
| Ondansetron Hcl | Ondansetron Hcl | 92 | 71 |
| Anastrozole | Anastrozole | 81 | 33 |
| Hydroxyurea | Hydroxyurea | 50 | 20 |
| Letrozole | Letrozole | 49 | 11 |
| Lidocaine-Prilocaine | Lidocaine/Prilocaine | 49 | 33 |
| Gabapentin | Gabapentin | 47 | 15 |
| Valacyclovir | Valacyclovir Hcl | 42 | 13 |
| Prednisone | Prednisone | 40 | 15 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 39 | 18 |
| Dexamethasone | Dexamethasone | 38 | 23 |
| Pantoprazole Sodium | Pantoprazole Sodium | 38 | 16 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 35 | 11 |
| Tramadol Hcl | Tramadol Hcl | 35 | 19 |
| Folic Acid | Folic Acid | 26 | suppressed |
| Tamoxifen Citrate | Tamoxifen Citrate | 25 | suppressed |
| Revlimid | Lenalidomide | 24 | suppressed |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 22 | suppressed |
| Alprazolam | Alprazolam | 22 | suppressed |
| Amlodipine Besylate | Amlodipine Besylate | 22 | suppressed |
| Xarelto | Rivaroxaban | 19 | suppressed |
| Nubeqa | Darolutamide | 18 | suppressed |
| Venclexta | Venetoclax | 18 | suppressed |
| Ninlaro | Ixazomib Citrate | 17 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 16 | suppressed |
| Potassium Chloride | Potassium Chloride | 16 | suppressed |
| Diazepam | Diazepam | 15 | suppressed |
| Lenalidomide | Lenalidomide | 15 | suppressed |
| Lenvima | Lenvatinib Mesylate | 15 | suppressed |
| Ondansetron Odt | Ondansetron | 15 | suppressed |
| Allopurinol | Allopurinol | 14 | suppressed |
| Cabometyx | Cabozantinib S-Malate | 14 | suppressed |
| Nystatin | Nystatin | 14 | suppressed |
| Tasigna | Nilotinib Hcl | 14 | suppressed |
| Brukinsa | Zanubrutinib | 13 | suppressed |
| Loperamide | Loperamide Hcl | 13 | suppressed |
| Fondaparinux Sodium | Fondaparinux Sodium | 12 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 12 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 12 | suppressed |
| Tagrisso | Osimertinib Mesylate | 12 | suppressed |
| Hydromorphone Hcl | Hydromorphone Hcl | 11 | suppressed |
| Omeprazole | Omeprazole | 11 | suppressed |
| Tamsulosin Hcl | Tamsulosin Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $2,959.97 · 146 records | E.R. Squibb & Sons, L.L.C. | AVMAPKI FAKZYNJA CO-PACK, BESREMI, BLENREP, BRUKINSA, CARVYKTI, DARZALEX, ELAHERE, ELZONRIS, EMRELIS, ENHERTU, ERLEADA, EVUSHELD, FRUZAQLA, Fabhalta, ICLUSIG, Itovebi, JAKAFI, JAYPIRCA, JEMPERLI, KEYTRUDA, KEYTRUDA QLEX, KISQALI, LIBTAYO, LORBRENA, LUTATHERA, LYNPARZA, NERLYNX, NIKTIMVO, Nubeqa, OJJAARA, OPDIVO, ORGOVYX, Orserdu, PYRUKYND, Polivy, RYBREVANT, RYTELO, SARCLISA, SCEMBLIX, Stivarga, TAGRISSO, TALVEY, TALZENNA, TECVAYLI, TEVIMBRA, Tecentriq, ULTOMIRIS, VENCLEXTA, VERZENIO, Vitrakvi, Vonjo, Vyloy, WAYRILZ, XPOVIO, XTANDI, Xofigo, ZEJULA, ZENPEP, clonoSEQ | 11 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Brukinsa play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error